Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II metronomic cisplatin + oral etoposide + bevacizumab in inoperable non‑squamous NSCLC (mPEBev)
2008-006051-40Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in Non-small cell lung cancer (NS-NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (3 arms), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoints: Objective response rate and Safety and tolerability. Started Sep 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2008-006051-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006051-40.